Search research articles
Contact Us
Filters
Showing results (31-40 of 83) with videos related to
Page
of 9
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
March 21, 2022
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
Nicholas J Robert, Janet L Espirito, Liwei Chen, et al.
Frontiers in Oncology
|
December 26, 2022
Identification of <i>HMGA2</i> as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer
Alexander Spira, Ahmad Awada, Nicolas Isambert, et al.
Cancer Management and Research
|
August 19, 2021
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
Maen Hussein, Marina Maglakelidze, Donald A Richards, et al.
The Oncologist
|
December 28, 2022
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
Alexander Spira, Michael S Wertheim, Edward J Kim, et al.
Therapeutic Innovation & Regulatory Science
|
September 1, 2020
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer
Phil Bonomi, Nina Stuccio, C J Delgra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2024
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer
Alessandro D Santin, Bradley R Corr, Alexander Spira, et al.
The Lancet. Oncology
|
September 15, 2022
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Vivek Subbiah, Jürgen Wolf, Bhavana Konda, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer
Benjamin Levy, Alexander Spira, Daniel Becker, et al.
JCO Precision Oncology
|
October 5, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Linda R Duska, Dmitriy Zamarin, Erica Hamilton, et al.
Oral Oncology
|
January 17, 2015
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno, Julie E Bauman, Charles Weissman, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 83) with videos related to
Sort By:
Page
of 9
Lung Cancer (Amsterdam, Netherlands)
|
March 21, 2022
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
Nicholas J Robert, Janet L Espirito, Liwei Chen, et al.
Frontiers in Oncology
|
December 26, 2022
Identification of <i>HMGA2</i> as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer
Alexander Spira, Ahmad Awada, Nicolas Isambert, et al.
Cancer Management and Research
|
August 19, 2021
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
Maen Hussein, Marina Maglakelidze, Donald A Richards, et al.
The Oncologist
|
December 28, 2022
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
Alexander Spira, Michael S Wertheim, Edward J Kim, et al.
Therapeutic Innovation & Regulatory Science
|
September 1, 2020
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer
Phil Bonomi, Nina Stuccio, C J Delgra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2024
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer
Alessandro D Santin, Bradley R Corr, Alexander Spira, et al.
The Lancet. Oncology
|
September 15, 2022
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Vivek Subbiah, Jürgen Wolf, Bhavana Konda, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer
Benjamin Levy, Alexander Spira, Daniel Becker, et al.
JCO Precision Oncology
|
October 5, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Linda R Duska, Dmitriy Zamarin, Erica Hamilton, et al.
Oral Oncology
|
January 17, 2015
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno, Julie E Bauman, Charles Weissman, et al.
Page
of 9